NCT04787354View on ClinicalTrials.gov

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

PHASE3RecruitingINTERVENTIONAL
Enrollment

976

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2027

Conditions
Gastric Cancer
Interventions
DRUG

Oxaliplatin

Oxaliplatin: 130 mg/m2/day

DRUG

Capecitabine

Capecitabine: 2,000 mg/m2/day

Trial Locations (1)

Unknown

RECRUITING

Hallym University Medical Center, Gyeonggi-do

All Listed Sponsors
lead

Hallym University Medical Center

OTHER